Royal Bank of Canada reissued their buy rating on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Sunday morning, AnalystRatings.com reports. Royal Bank of Canada currently has a $66.00 price objective on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently weighed in on EGRX. BidaskClub raised shares of Eagle Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday. ValuEngine raised shares of Eagle Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, April 23rd. Mizuho reissued a hold rating and issued a $50.00 price target on shares of Eagle Pharmaceuticals in a research note on Wednesday, April 24th. Cantor Fitzgerald reissued a hold rating and issued a $58.00 price target on shares of Eagle Pharmaceuticals in a research note on Tuesday, May 7th. Finally, Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, July 10th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $58.20.

NASDAQ:EGRX opened at $57.71 on Friday. The stock has a 50-day simple moving average of $55.30. The company has a current ratio of 3.59, a quick ratio of 3.36 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $793.84 million, a P/E ratio of 27.61 and a beta of 1.44. Eagle Pharmaceuticals has a twelve month low of $36.03 and a twelve month high of $82.33.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.17. The firm had revenue of $56.70 million for the quarter, compared to the consensus estimate of $53.61 million. Eagle Pharmaceuticals had a net margin of 19.79% and a return on equity of 24.10%. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period last year, the firm posted $0.99 earnings per share. As a group, analysts expect that Eagle Pharmaceuticals will post 1.75 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of EGRX. PNC Financial Services Group Inc. raised its stake in Eagle Pharmaceuticals by 156.8% during the first quarter. PNC Financial Services Group Inc. now owns 642 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 392 shares during the period. Financial Gravity Wealth Inc. purchased a new position in Eagle Pharmaceuticals during the second quarter worth about $33,000. First Quadrant L P CA purchased a new position in Eagle Pharmaceuticals during the second quarter worth about $34,000. NumerixS Investment Technologies Inc purchased a new position in Eagle Pharmaceuticals during the second quarter worth about $39,000. Finally, Bank of Montreal Can raised its stake in Eagle Pharmaceuticals by 395.0% during the second quarter. Bank of Montreal Can now owns 1,277 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 1,019 shares during the period. 96.61% of the stock is currently owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

See Also: Short Selling

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.